Use of antifungal combination therapy: Agents, order, and timing

Current Fungal Infection Reports

Volumn 4, Issue 2, 2010, Pages 87-95

  Johnson, Melissa D ^a   Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Antifungal agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cryptococcosis; Cryptococcus; Drug therapy, combination; Echinocandins; Fluconazole; Flucytosine; Fungi; Hematopoietic stem cell transplantation; Imidazoles; Meningitis, cryptococcal; Mucormycosis; Mycoses; Triazoles; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ADD ON THERAPY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW SUPPRESSION; CANDIDEMIA; CANDIDIASIS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL WALL; CEREBROSPINAL FLUID ANALYSIS; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; FUNGAL CELL; HISTOPLASMOSIS; HUMAN; INJECTION SITE REACTION; INTERVERTEBRAL DISK DEGENERATION; LIPOPHILICITY; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MYCOSIS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERITONITIS; PSEUDALLESCHERIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPOROTRICHOSIS; STEM CELL TRANSPLANTATION; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TREATMENT RESPONSE; ZYGOMYCOSIS;

EID: 79952190110     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0018-6     Document Type: Review

References (63)

1. Lewis RE: Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy 2006, 26:61 S-67 S.
2. Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001, 21:149 S-164 S.
3. Kontoyiannis DP, Lewis RE: Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004, 126:165-175. (Pubitemid 38961935)
4. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715. (Pubitemid 38280314)
5. Powers JH: Considerations in clinical trials of combination antifungal therapy. Clin Infect Dis 2004, 39(Suppl 4):S228-S235.
6. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH: Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003, 37:415-425.
7. Ellis D: Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002, 49(Suppl 1):7-10.
8. Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360. (Pubitemid 351265310)
9. Fera MT, La Camera E, De Sarro A: New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009, 7:981-998. This paper describes newer azole and echinocandin antifungal agents with respect to pharmacology and microbiologic activity
10. Manavathu EK, Alangaden GJ, Chandrasekar PH: Differential activity of triazoles in two-drug combinations with the echino-candin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003, 51:1423-1425. (Pubitemid 36748933)
11. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415. (Pubitemid 34851833)
12. Arikan S, Sancak B, Alp S, et al.: Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008, 46:567-573.
13. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al.: Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006, 50:917-921. (Pubitemid 43327795)
14. Gonzalez GM: In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009, 47:71-76. This in vitro study compared the microbiologic activity of newer azoles for rare molds and dimorphic fungi
15. Fisher BT, Chiller TM, Prasad PA, et al.: Hospitalizations for coccidioidomycosis at forty-one children's hospitals in the United States. Pediatr Infect Dis J 2010, 29:243-247.
16. Wheat LJ, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
17. Kauffman CA, Bustamante B, Chapman SW, Pappas PG: Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:1255-1265.
18. Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801-1812.
19. Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217-1223. (Pubitemid 41532662)
20. Freifeld A, Proia L, Andes D, et al.: Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648-1651.
21. Catanzaro A, Cloud GA, Stevens DA, et al.: Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007, 45:562-568. (Pubitemid 47328635)
22. Kirkpatrick WR, Coco BJ, Patterson TF: Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006, 50:1567-1569.
23. Ernst EJ, Klepser ME, Pfaller MA: In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. Diagn Microbiol Infect Dis 1998, 32:205-210.
24. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228. (Pubitemid 36629929)
25. Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764-1767. (Pubitemid 38698379)
26. Pappas PG, Chetchotisakd P, Larsen RA, et al.: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48:1775-1783. This open-label phase 2 trial compared the combination of amphotericin B and fluconazole (at high or low dosages) versus amphotericin B alone as induction therapy for HIV-associated cryptococcal meningitis.
27. Chaux GE: Combination antifungal therapy for invasive mold infections involving polyenes: a case report and brief review of the literature. Inf Dis Clin Pract 2010, 18:7-15. This review summarizes cases in which lipid formulations of amphotericin B were used in combination with other antifungals for the management of invasive mold infections.
28. Patterson TF, Boucher HW, Herbrecht R, et al.: Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005, 41:1448-1452. (Pubitemid 41579987)
29. Cornely OA, Maertens J, Bresnik M, et al.: Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B. J Antimicrob Chemother 2010, 65:114-117. This analysis suggested that prior azole prophylactic therapy or early empiric therapy did not affect overall response or mortality among patients who received LAmB therapy for invasive filamentous fungal infection
30. Canton E, Peman J, Gobernado M, et al.: Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods. Antimicrob Agents Chemother 2005, 49:1593-1596. (Pubitemid 40463398)
31. Gil-Lamaignere C, Muller FM: Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int J Antimicrob Agents 2004, 23:520-523. (Pubitemid 38569606)
32. Garcia-Effron G, Gomez-Lopez A, Mellado E, et al.: In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004, 53:1086-1089.
33. Mosquera J, Sharp A, Moore CB, et al.: In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5- flucytosine against Aspergillus spp. J Antimicrob Chemother 2002, 50:189-194.
34. Kirkpatrick WR, Vallor AC, McAtee RK, et al.: Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob Agents Chemother 2005, 49:4751-4753. (Pubitemid 41552609)
35. Ghannoum MA, Elewski B: Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999, 6:921-923. (Pubitemid 29529988)
36. Rothe A, Seibold M, Hoppe T, et al.: Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004, 83:394-397. (Pubitemid 38684455)
37. Li JY, Yong TY, Grove DI, Coates PT: Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008, 10:63-65. (Pubitemid 351171314)
38. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ: Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007, 39:87-90. (Pubitemid 46277156)
39. Gosbell IB, Toumasatos V, Yong J, et al.: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003, 46:233-236. (Pubitemid 36808246)
40. Kesson AM, Bellemore MC, O'Mara TJ, et al.: Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009, 48:1257-1261.
41. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother 2009, 43:1647-1657.
42. Tunger O, Bayram H, Degerli K, et al.: Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. Saudi Med J 2008, 29:728-733.
43. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568. (Pubitemid 34793464)
44. MacCallum DM, Whyte JA, Odds FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005, 49:3697-3701. (Pubitemid 41233020)
45. Petraitis V, Petraitiene R, Hope WW, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009, 53:2382-2391.
46. Ibrahim AS, Gebremariam T, Fu Y, et al.: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556-1558. (Pubitemid 351522035)
47. Rieger CT, Ostermann H, Kolb HJ, et al.: A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Ann Hematol 2008, 87:915-922. This small, retrospective study of combination antifungal therapy for the treatment of invasive fungal infections in patients with hematologic malignancies suggested that combination therapy was feasible in this population
48. Bland CM, Thomas S: Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans. Ann Pharmacother 2009, 43:528-531.
49. Nivoix Y, Zamfir A, Lutun P, et al.: Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006, 52:67-74. (Pubitemid 43115510)
50. Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320-326. (Pubitemid 43255714)
51. Marr KA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802. (Pubitemid 39244292)
52. Denning DW, Marr KA, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337-349. (Pubitemid 44524711)
53. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al.: Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009, 11:89-93. This study describes multicenter experience with micafungin in managing invasive aspergillosis in hematopoietic stem cell transplant recipients. Most patients received combination anti-fungal therapy for infections that were refractory to initial therapy.
54. Thomas A, Korb V, Guillemain R, et al.: Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Therapeut 2010, 35:49-53. This small, retrospective study reported efficacy of voriconazole plus caspofungin for management of invasive aspergillosis in lung transplant recipients
55. Maertens J, Glasmacher A, Herbrecht R, et al.: Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888-2897. (Pubitemid 44937044)
56. Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371. (Pubitemid 352009357)
57. Reed C, Ibrahim A, Edwards JE Jr, et al.: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968-3969. (Pubitemid 44684931)
58. Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
59. Nussbaum JC, Jackson A, Namarika D, et al.: Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338-344. This randomized, prospective clinical trial established efficacy of oral fluconazole plus flucytosine compared with high-dose fluconazole monotherapy for induction therapy of HIV-associated cryptococcal meningitis.
60. Natarajan G, Lulic-Botica M, Rongkavilit C, et al.: Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25:770-777. (Pubitemid 43019041)
61. Wertz KK, Pretzlaff RK: Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med 2004, 5:181-183.
62. Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
63. Falcone M, Barzaghi N, Carosi G, et al.: Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 2009, 88:160-168.